Deucravacitinib in PG

Dartmouth Health

Status and phase

Begins enrollment in 2 months

Early Phase 1

Conditions

Pyoderma Gangrenosum

Treatments

Drug: Deucravacitinib

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT05821374

STUDY02001753

Details and patient eligibility

About

The main goal of this study is to see if the study drug called "Deucravacitinib" is safe and effective in treating people with pyoderma gangrenosum (PG).

Enrollment

10 estimated patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Men and women between the ages of 18-70 years old
Diagnosed with pyoderma gangrenosum requiring one major and at least 4 minor criteria
Women must not be pregnant, lactating, or planning pregnancy during the study period
Women of child-bearing potential must be on birth control for the duration of the treatment period.
Subjects must agree to the use of at least one of the following contraception methods for the entire duration of the study until at least 30 days after taking their last dose of study drug:
Women: Hormonal contraception (oral, injections, patch, implant, or vaginal-ring); Spiral (with or without hormones); any sterilization methods; a partner who has had a vasectomy; or sexual abstinence.
Other acceptable methods of contraception are male or female condoms (with or without spermicide) or a cap, diaphragm, or sponge with spermicide.
Willing to discontinue topical and/or systemic therapies, with the exception of oral rescue therapy with steroids.
The wash period for systemic therapies will largely depend on the specific treatment but, in general, will be at least 6 months for biologics and 3 months for other immune- suppressants such as cyclosporine, mycophenolate mofetil, methotrexate, etc. No wash out period is required for topicals.
Capable and willing to sign Institutional Review Board/IEC-approved written informed consent form in accordance with regulatory and institutional guidelines before the performance of any protocol-related procedures.

Exclusion criteria

Patient under 18 years of age.
Patients with a history of inflammatory bowel disease.
Patients on systemic immunosuppressive/immune modulating therapy including: oral steroids, cyclosporine, mycophenolate mofetil, methotrexate, Azathioprine or TNFα inhibitor at time of starting deucravacitinib.
Patients currently enrolled in another investigational study.
Patients with a history or evidence of active infection and/or febrile illness within 7 days; or serious infection requiring antibiotic treatment within 30 days
Hepatitis C virus (HCV): subjects known to be positive for anti-HCV antibody or for HCV RNA detectable by polymerase chain reaction (PCR)
Hepatitis B virus (HBV): subjects known to be positive for hepatitis B surface antigen or for HBV DNA detectable by PCR
Human Immunodeficiency Virus (HIV) infection: subjects known to be HIV positive
History of active or inadequately treated latent tuberculosis (TB)
Known or suspected systemic or skin autoimmune disorder other than pyoderma gangrenosum
Any unstable major illness or evidence of unstable condition of major organ systems including psychiatric
Cancer or history of lymphoproliferative disease within last 5 years; exception is cutaneous basal cell carcinoma or squamous cell carcinoma that has been treated.
Major surgery within the last 4 weeks
Live vaccines within the last 60 days
Leukopenia (absolute WBC count < 3000/mm3); Lymphopenia (ALC < 500/mm3); Neutropenia (ANC < 1000/mm3)
Thrombocytopenia (platelet count < 100,000/mm3; Anemia (hemoglobin < 9.0g/dL)
ALT/AST > 3 X ULN and/or Total, unconjugated, and/or conjugated bilirubin > 2 X ULN within 28 days of dosing